C-FMS inhibitors: A patent review

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 2, 2011, Pages 147-165

  Burns, Christopher J ^a   Wilks, Andrew F ^b,c  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b SYNthesis Med Chem   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

CSF; CSF 1; FMS; kinase; kinase inhibitor

Indexed keywords

ANILIDE; BENZOTHIAZOLE DERIVATIVE; PYRAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; BONE METABOLISM; DENDRITIC CELL; DRUG SPECIFICITY; HUMAN; INFLAMMATORY DISEASE; INNATE IMMUNITY; LANGERHANS CELL; MACROPHAGE FUNCTION; MICROGLIA; NEOPLASM; NONHUMAN; OSTEOCLAST; PATENT; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; CELL LINEAGE; DENDRITIC CELLS; HUMANS; INTERLEUKINS; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; PATENTS AS TOPIC; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR;

EID: 79952937014     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.545348     Document Type: Review

References (135)

1. Fredriksson L, Li H, Eriksson U. The PDGF family: Four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004;15(4):197-204 (Pubitemid 38781045)
2. Williams DE, Eisenman J, Baird A, et al Identification of a ligand for the c-kit proto-oncogene. Cell 1990;63(1):167-74
3. Lyman SD, James L, Vanden Bos T, et al Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells. Cell 1993;75(6):1157-67 (Pubitemid 24006112)
4. Sherr CJ, Rettenmier CW, Sacca R, et al The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 1985;41(3):665-76 (Pubitemid 15243374)
5. Lin H, Lee E, Hestir K, et al Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 2008;320(5877):807-11 . An important demonstration of a second ligand for c-FMS. (Pubitemid 351929632)
6. Hamilton JA. CSF-1 signal transduction. J Leukoc Biol 1997;62(2):145-55 (Pubitemid 27380786)
7. Walter M, Lucet IS, Patel O, et al The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain. J Mol Biol 2007;367(3):839-47 Crystal structure of fms kinase domain in apo form. (Pubitemid 46330380)
8. Schubert C, Schalk-Hihi C, Struble GT, et al Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors. J Biol Chem 2007;282(6):4094-101 The first crystal structure of liganded fms kinase domain reported. (Pubitemid 47084443)
9. Huang H, Hutta DA, Rinker JM, et al Pyrido[2,3-d]pyrimidin-5-ones: A novel class of anti-inflammatory macrophage colony-stimulating factor-1 receptor inhibitors. J Med Chem 2009;52(4):1081-99
10. Meyers MJ, Pelc M, Kamtekar S, et al Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode. Bioorg Med Chem Lett 2010;20(5):1543-7
11. Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol 2006;18(1):39-48 (Pubitemid 43049646)
12. Douglass TG, Driggers L, Zhang JG, et al Macrophage colony stimulating factor: Not just for macrophages anymore! A gateway into complex biologies. Int Immunopharmacol 2008;8(10):1354-76
13. Takashima A, Edelbaum D, Kitajima T, et al Colony-stimulating factor-1 secreted by fibroblasts promotes the growth of dendritic cell lines (XS series) derived from murine epidermis. J Immunol 1995;154(10):5128-35
14. Ginhoux F, Tacke F, Angeli V, et al Langerhans cells arise from monocytes in vivo. Nat Immunol 2006;7(3):265-73
15. Fancke B, Suter M, Hochrein H, O'Keeffe M. M-CSF: A novel plasmacytoid and conventional dendritic cell poietin. Blood 2008;111(1):150-9
16. Pandit J, Bohm A, Jancarik J, et al Three-dimensional structure of dimeric human recombinant macrophage colony-stimulating factor. Science 1992;258(5086):1358-62 (Pubitemid 23007788)
17. Mackaness GB. The immunological basis of acquired cellular resistance. J Exp Med 1964;120:105-20
18. Porcheray F, Viaud S, Rimaniol AC, et al Macrophage activation switching: An asset for the resolution of inflammation. Clin Exp Immunol 2005;142(3):481-9 (Pubitemid 41719844)
19. Mantovani A, Sozzani S, Locati M, et al Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23(11):549-55 An important review on the polarization of macrophages, M1 vs M2. (Pubitemid 35223554)
20. Ginhoux F, Tacke F, Angeli V, et al Langerhans cells arise from monocytes in vivo. Nat Immunol 2006;7(3):265-73
21. Takashima A, Kitajima T. T cell-mediated terminal maturation of dendritic cells, a critical transition into fully potent antigen presenting cells. Pathol Biol (Paris) 1998;46(1):53-60 (Pubitemid 28112767)
22. Nakajima K, Kohsaka S. Microglia: Activation and their significance in the central nervous system. J Biochem 2001;130(2):169-75 (Pubitemid 32785862)
23. Imai Y, Kohsaka S. Intracellular signaling in M-CSF-induced microglia activation: Role of Iba1. Glia 2002;40(2):164-74 (Pubitemid 35337374)
24. Kondo Y, Lemere C, Seabrook T. Osteopetrotic (op/op) mice have reduced microglia, no Abeta deposition, and no changes in dopaminergic neurons. J Neuroinflamm 2007;4(1):31
25. Nijweide PJ, Burger EH, Feyen JH. Cells of bone: Proliferation, differentiation, and hormonal regulation. Physiol Rev 1986;66(4):855-86 (Pubitemid 17181295)
26. Lacey DL, Timms E, Tan HL, et al Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93(2):165-76 (Pubitemid 28180851)
27. Teitelbaum SL. Osteoclasts: What do they do and how do they do it? Am J Pathol 2007;170(2):427-35 (Pubitemid 47339379)
28. Yasuda H, Shima N, Nakagawa N, et al Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95(7):3597-602
29. Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW, et al Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/ op) mouse. Proc Natl Acad Sci USA 1990;87(12):4828-32 A demonstration that CSF-1 is absent in op/op mice.
30. Yoshida H, Hayashi S, Kunisada T, et al The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990;345(6274):442-4 . A genetic demonstration that CSF-1 is mutated in op/op mice. (Pubitemid 120014957)
31. Campbell IK, Rich MJ, Bischof RJ, Hamilton JA. The colony-stimulating factors and collagen-induced arthritis: Exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF. J Leukoc Biol 2000;68(1):144-50 The paper describes the critical role of CSF-1 signaling in arthritis.
32. Isbel NM, Nikolic-Paterson DJ, Hill PA, et al Local macrophage proliferation correlates with increased renal M-CSF expression in human glomerulonephritis. Nephrol Dial Transplant 2001;16(8):1638-47 (Pubitemid 32750457)
33. Yang PT, Xiao WG, Zhao LJ, et al Increase in the level of macrophage colony-stimulating factor in patients with systemic lupus erythematosus. Ann Rheum Dis 2008;67(3):429-30 (Pubitemid 351281286)
34. Klebl FH, Olsen JE, Jain S, Doe WF. Expression of macrophage-colony stimulating factor in normal and inflammatory bowel disease intestine. J Pathol 2001;195(5):609-15 (Pubitemid 34030800)
35. Rallidis LS, Zolindaki MG, Pentzeridis PC, et al Raised concentrations of macrophage colony stimulating factor in severe unstable angina beyond the acute phase are strongly predictive of long term outcome. Heart 2004;90(1):25-9 (Pubitemid 38064537)
36. Kreipe H, Radzun HJ, Heidorn K, et al Proliferation, macrophage colony-stimulating factor, and macrophage colony-stimulating factorreceptor expression of alveolar macrophages in active sarcoidosis. Lab Invest 1990;62(6):697-703 (Pubitemid 20213687)
37. Retamales I, Elliott WM, Meshi B, et al Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001;164(3):469-73 (Pubitemid 32778218)
38. Davis TA, Lennon G. Mice with a regenerative wound healing capacity and an SLE autoimmune phenotype contain elevated numbers of circulating and marrow-derived macrophage progenitor cells. Blood Cells Mol Dis 2005;34(1):17-25 (Pubitemid 40017975)
39. Lenda DM, Kikawada E, Stanley ER, Kelley VR. Reduced macrophage recruitment, proliferation, and activation in colony-stimulating factor-1-deficient mice results in decreased tubular apoptosis during renal inflammation. J Immunol 2003;170(6):3254-62 (Pubitemid 36302203)
40. Lenda DM, Stanley ER, Kelley VR. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice. J Immunol 2004;173(7):4744-54 (Pubitemid 39280711)
41. Le Meur Y, Jose MD, Mu W, et al Macrophage colony-stimulating factor expression and macrophage accumulation in renal allograft rejection. Transplantation 2002;73(8):1318-24 (Pubitemid 34454282)
42. Welsing PM, van Gestel AM, Swinkels HL, et al The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44(9):2009-17 (Pubitemid 33644042)
43. Chu CQ, Field M, Allard S, et al Detection of cytokines at the cartilage/ pannus junction in patients with rheumatoid arthritis: Implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 1992;31(10):653-61
44. Campbell IK, Ianches G, Hamilton JA. Production of macrophage colony-stimulating factor (M-CSF) by human articular cartilage and chondrocytes. Modulation by interleukin-1 and tumor necrosis factor [alpha]. Biochimica et Biophysica Acta (BBA) - Mol Basis Dis 1993;1182(1):57-63 (Pubitemid 23233674)
45. Nakano K, Okada Y, Saito K, et al Rheumatoid synovial endothelial cells produce macrophage colony-stimulating factor leading to osteoclastogenesis in rheumatoid arthritis. Rheumatology (Oxford) 2007;46(4):597-603 (Pubitemid 46523302)
46. Rioja I, Hughes FJ, Sharp CH, et al Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum 2008;58(8):2257-67
47. Komano Y, Nanki T, Hayashida K, et al Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts. Arthritis Res Ther 2006;8(5):R152
48. Kitaura H, Zhou P, Kim H-J, et al M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Investig 2005;115(12):3418-27 An important paper in defining the critical role of CSF-1 in bone osteolysis. (Pubitemid 43121830)
49. Menaa C, Barsony J, Reddy SV, et al 1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease. J Bone Miner Res 2000;15(2):228-36 (Pubitemid 30095709)
50. Neale SD, Smith R, Wass JA, Athanasou NA. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL. Bone 2000;27(3):409-16 (Pubitemid 30658125)
51. Menaa C, Reddy SV, Kurihara N, et al Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest 2000;105(12):1833-8 (Pubitemid 30421765)
52. Cody JD, Singer FR, Roodman GD, et al Genetic linkage of Paget disease of the bone to chromosome 18q. Am J Hum Genet 1997;61(5):1117-22 (Pubitemid 27492320)
53. Laurin N, Brown JP, Lemainque A, et al Paget disease of bone: Mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet 2001;69(3):528-43 (Pubitemid 32777692)
54. Haslam SI, Van Hul W, Morales-Piga A, et al Paget's disease of bone: Evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res 1998;13(6):911-17 (Pubitemid 28265268)
55. Roodman GD, Kurihara N, Ohsaki Y, et al Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest 1992;89(1):46-52
56. Hoyland JA, Freemont AJ, Sharpe PT. Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in Paget's disease. J Bone Miner Res 1994;9(1):75-80
57. Neale SD, Schulze E, Smith R, Athanasou NA. The influence of serum cytokines and growth factors on osteoclast formation in Paget's disease. QJM 2002;95(4):233-40 (Pubitemid 34413730)
58. Rubin J, Fan X, Thornton D, et al Regulation of murine osteoblast macrophage colony-stimulating factor production by 1,25(OH)2D3. Calcif Tissue Int 1996;59(4):291-6 (Pubitemid 26353025)
59. Gorer PA. Some recent work on tumor immunity. Adv Cancer Res 1956;4:149-86
60. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: The macrophage connection. J Leukoc Biol 1998;64(3):275-90 (Pubitemid 28409233)
61. Lin EY, Li JF, Gnatovskiy L, et al Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006;66(23):11238-46 (Pubitemid 46009952)
62. Kacinski BM. CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann Med. 1995;27(1):79-85
63. Kacinski BM. CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol Reprod Dev 1997;46(1):71-4 (Pubitemid 27021356)
64. Xu FJ, Ramakrishnan S, Daly L, et al Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol. 1991;165(5 Pt 1):1356-62
65. Mroczko B, Groblewska M, Wereszczynska-Siemiatkowska U, et al Serum macrophagecolony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta 2007;380:208-12 (Pubitemid 46498063)
66. Mroczko B, Szmitkowski M, Okulczyk B. Granulocyte-colony stimulating factor (G-CSF) and macrophage colony stimulating factor (M-CSF) in colorectal cancer patients. Clin Chem Lab Med 2002;40:351-5 (Pubitemid 34546230)
67. Khatami M. Standardizing cancer biomarkers criteria: Data elements as a foundation for a database. Inflammatory mediator/M-CSF as model marker. Cell Biochem Biophys 2007;47:187-98 (Pubitemid 47338361)
68. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 2002;196(3):254-65 (Pubitemid 34189413)
69. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4(1):71-8 . An excellent review of tumor-associated macrophages, their role and mechanisms in promoting tumor growth and metastasis. (Pubitemid 38082155)
70. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66(2):605-12 (Pubitemid 43165918)
71. Aharinejad S, Paulus P, Sioud M, et al Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res 2004;64(15):5378-84 (Pubitemid 39006559)
72. Paulus P, Stanley ER, Schafer R, et al Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res 2006;66(8):4349-56
73. Kubota Y, Takubo K, Shimizu T, et al M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med 2009;206(5):1089-102
74. Manthey CL, Johnson DL, Illig CR, et al JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther 2009;8(11):3151-61
75. Biswas SK, Gangi L, Paul S, et al A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006;107:2112-22 (Pubitemid 43289397)
76. Saccani A, Schioppa T, Porta C, et al p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 2006;66:11432-40 (Pubitemid 46009975)
77. Coussens LM, Werb Z. Inflamm Cancer Nat 2002;420:860-67
78. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-12 (Pubitemid 43165918)
79. Nowicki A, Szenajch J, Ostrowska G, et al Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: Evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int J Cancer 1996;65(1):112-19 The first demonstration that CSF-1-driven tumor-associated macrophages assist in tumor growth. (Pubitemid 26030942)
80. Patel S, Player MR. Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease. Curr Top Med Chem 2009;9:599-610
81. AstraZeneca Ltd. Chemical Compounds. WO2006067445; 2006
82. AstraZeneca Ltd. Chemical Compounds. WO2007071955; 2007
83. Scott DA, Aquila BM, Bebernitz GA, et al Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer. Bioorg Med Chem Lett 2008;18(17):4794-7
84. Dimensional Pharmaceuticals, Inc. c-FMS kinase inhibitors WO2004096795; 2004
85. Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase. WO2006047503; 2006
86. Janssen Pharmaceutica N.V. Inhibitors of c-FMS kinase. WO2006047277; 2006
87. Janssen Pharmaceutica N.V. Aromatic amides as inhibitors of c-FMS kinase. WO2006047504; 2006
88. Janssen Pharmaceutica N.V. Inhibitors of c-FMS kinase. WO2007124322; 2007
89. Janssen Pharmaceutica N.V. c-fms kinase inhibitors. WO2007123516; 2007
90. Janssen Pharmaceutica N.V. Use of cfms inhibitor for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer. WO2009058801; 2009
91. Patch RJ, Brandt BM, Asgari D, et al Potent 2'-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents. Bioorg Med Chem Lett 2007;17(22):6070-4 (Pubitemid 47552848)
92. Illig CR, Chen J, Wall MJ, et al Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. Bioorg Med Chem Lett 2008;18(5):1642-8 (Pubitemid 351343803)
93. Meegalla SK, Wall MJ, Chen J, et al Structure-based optimization of a potent class of arylamide FMS inhibitors. Bioorg Med Chem Lett 2008;18(12):3632-7 (Pubitemid 351795594)
94. GlaxoSmithKline. Crystal Structure of liganded cFMS kinase domain. US20040002145; 2004
95. Conway JG, McDonald B, Parham J, et al Inhibition of colony- stimulatingfactor- 1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci USA 2005;102(44):16078-83 (Pubitemid 41552870)
96. Conway JG, Pink H, Bergquist ML, et al Effects of the cFMS Kinase Inhibitor 5-(3-Methoxy-4-((4- methoxybenzyl)oxy)benzyl)pyrimidine- 2,4-diamine (GW2580) in Normal and Arthritic Rats. J Pharmacol Exp Ther 2008;326(1):41-50 (Pubitemid 351872132)
97. Pfizer, Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors. WO2006021881; 2006
98. Cytopia Research Pty Ltd. Inhibitors of Kinase Activity. WO2008058341; 2008
99. Burns CJ, Harte MF, Bu X, et al Discovery of 2-([alpha]- methylbenzylamino) pyrazines as potent Type II inhibitors of FMS. Bioorg Med Chem Lett 2009;19(4):1206-9
100. Kirin Brewery. Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor. WO200309328; English version EP1535910; 2003
101. Ohno H, Kubo K, Murooka H, et al A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther 2006;5(11):2634-43 The first publication describing a small molecule fms inhibitor with activity against bone osteolysis in a xenograft study. (Pubitemid 44848990)
102. Ohno H, Uemura Y, Murooka H, et al The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur J Immunol 2008;38(1):283-91
103. Uemura Y, Ohno H, Ohzeki Y, et al The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis. J Neuroimmunol 2008;195(1-2):73-80
104. Kubota Y, Takubo K, Shimizu T, et al M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med 2009;206(5):1089-102
105. Smalley Jr TL, Chamberlain SD, Mills WY, et al Synthesis of novel anilinoquinolines as c-fms inhibitors. Bioorg Med Chem Lett 2007;17(22):6257-60 (Pubitemid 47552819)
106. AstraZeneca Ltd. 4-Anilinoquinoline-3- Carboxamides As CSF-1R Kinase Inhibitors. WO2007119046; 2007
107. AstraZeneca Ltd. Chemical Compounds. WO2008056148; 2008
108. Scott DA, Balliet CL, Cook DJ, et al Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase. Bioorg Med Chem Lett 2009;19(3):697-700
109. Scott DA, Bell KJ, Campbell CT, et al 3-Amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profile. Bioorg Med Chem Lett 2009;19(3):701-5
110. Drew L, Bell K, Dakin L, et al The selective CSF-1R inhibitor AZ683 reduces tumor associated macrophages and inhibits growth of breast cancer xenograft models (Abstract nr 259). In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 18 - 22 April 2009; Denver, CO. Philadelphia, PA, AACR; 2009
111. Plexxikon, Inc. Compounds modulating c-kit and c-fms activity and uses therefor. WO2007013896; 2007
112. Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor. WO2008080015; 2008
113. Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor. WO2008063888; 2008
114. Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor. WO2008064265; 2008
115. Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor. WO2009143018; 2009
116. Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor. US20090306086; 2009
117. Guo J, Marcotte PA, McCall JO, et al Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther 2006;5(4):1007-13 (Pubitemid 43724601)
118. West BL, DeNardo DG, Tsai J, et al Efficacy of the selective CSF-1R kinase inhibitor PLX3397 in mouse models of tumor growth and bone metastasis. (Abstract nr 3850). In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 17 - 21 April 2010; Washington, DC. Philadelphia, PA, AACR; 2010
119. Plexxikon's PLX3397 Preclinical Data Demonstrate Potential of Novel, "First-in-Class" Cancer Drug. Plexxikon, Inc. press release; 2010. Available from: Www.plexxikon. com/view.cfm/73/Press-Releases [Last accessed 8 August 2010]
120. El-Gamal MI, Jung MH, Oh CH. Discovery of a new potent bisamide FMS kinase inhibitor. Bioorg Med Chem Lett 2010;20(11):3216-18
121. Korea Institute of Science and Technology. Novel pyrrolo[3,2-b] pyridine derivatives or pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for prevention or treatment of melanoma containing the same as an active ingredient. KR20100047998; 2010
122. Janssen Pharmaceutica N.V. Quinolinone derivatives as inhibitors of c-fms kinase WO2005009967; 2005
123. Wall MJ, Chen J, Meegalla S, et al Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors. Bioorg Med Chem Lett 2008;18(6):2097-102 (Pubitemid 351391842)
124. Janssen Pharmaceutica N.V. 5-Oxo-5,8- dihydro-pyrido-pyrimidines as inhibitors of c-FMS kinase. WO2007033137; 2007
125. Janssen Pharmaceutica N.V. 5-Oxo-5,8- dihydro-pyrido-pyrimidines as inhibitors of c-FMS kinase. WO2007033232; 2007
126. Janssen Pharmaceutica N.V. 5-Oxo-5,8- dihydro-pyrido-pyrimidines as inhibitors of c-FMS kinase. WO2008055013
127. Novartis AG. 6-O-Substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF1R signalling. WO2007121484; 2007
128. Novartis AG. 2 CSF-1R inhibitors, compositions, and methods of use. WO200814406; 2008
129. Novartis AG. 2 CSF-1R inhibitors, compositions, and methods of use. WO2009050228; 2009
130. Wiesmann M, Daniel DL, Pryer N, et al BLZ945, a selective c-fms (CSF-1R) kinase inhibitor for the suppression of tumor-induced osteolytic lesions in bone (Abstract nr 3629). In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 17 -21 April 2010; Washington, DC. Philadelphia, PA, AACR; 2010
131. Fedorov O, Muller S, Knapp S. The (un)targeted cancer kinome. Nat Chem Biol 2010;6(3):166-9
132. Buchdunger E, Cioffi CL, Law N, et al Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295(1):139-45
133. Dewar AL, Cambareri AC, Zannettino AC, et al Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005;105(8):3127-32
134. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2(7):358-64 (Pubitemid 43936934)
135. Swinney DC. Biochemical mechanisms of drug action: What does it take for success? Nat Rev Drug Discov 2004;3(9):801-8 (Pubitemid 39242832)